Jenkem Technology Co., Ltd.

ACTIVE

Floor 3, Floor C-1, Beilingdi, Zhongguancun Dongsheng Technology Park, No.66, Xixiaokou Road, Haidian District, Beijing, 北京市, Chinawww.jenkem.comPrivate298 employeesEstablished: 2001-10-09

Part of Jenkem Technology Co., Ltd.

Clinical Trials

2 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2001

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

40.0%

Phase 2

40.0%

Phase 3

20.0%

Trial Status Distribution

Completed

20.0%

Not yet recruiting

40.0%

Recruiting

20.0%

Unknown

20.0%

Clinical Trials

Trials sponsored by this organization (5)

JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases

Phase 2

Not yet recruiting

interventional

Sep 202425 participants

JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer

Phase 3

Not yet recruiting

interventional

Sep 2024394 participants

JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)

Phase 2

Recruiting

interventional

Oct 202225 participants

Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC

Phase 1

Unknown

interventional

Nov 202163 participants

Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor

Phase 1

Completed

interventional

May 201825 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations